

INVESTIGATIVE REPORT

Neisseria gonorrhoeae Antibiotic Resistance in Paris, 2005 to 2007: Implications for Treatment Guidelines

David FARHI¹, Claire HOTZ¹, Hélène POUPET², Philippe GERHARDT¹, Philippe MORAND², Claire POYART², Patrice SEDNAOUI³, Marie-Françoise AVRIL¹ and Nicolas DUPIN¹

Departments of ¹Dermatology and Venereology, UPRES1833 Centre National de Référence de la Syphilis, and ²Bacteriology, Cochin Hospital, APHP, Faculté de Médecine – Université Paris Descartes, and ³Centre National de Référence des Gonocoques, Institut Alfred Fournier, Paris, France

Quinolone-resistant *Neisseria gonorrhoeae* rates have increased worldwide since 1994. The objective of this study was to appraise: (i) the antimicrobial susceptibility of *Neisseria gonorrhoeae* in a venereology clinic in Paris, between 2005 and 2007; and (ii) the factors associated with quinolone-resistant *N. gonorrhoeae*. A prospective study of consecutive cases was performed for the period 2005 to 2007. Susceptibility of *N. gonorrhoeae* to five antibiotics (ciprofloxacin, ceftriaxone, spectinomycin, penicillin G and tetracycline) was tested systematically. Clinical and epidemiological data were collected using a standardized form. Male-to-female sex ratio was 22.0. Median age was 30.0 years. Of 115 cases, 84 occurred in men having sex with men (72.6%) and 22 involved the anorectal area (19.1%). The rate of quinolone-resistant *N. gonorrhoeae* was 37.4% (43/115), without significant association with gender, age, sexual behaviour, past history of sexually transmitted diseases and susceptibility to other antibiotics. All *N. gonorrhoeae* were susceptible to ceftriaxone and spectinomycin. The rate of quinolone-resistant *N. gonorrhoeae* in Paris has been increasing since 2004. Ceftriaxone remains the gold standard treatment. **Key words: *Neisseria gonorrhoeae*; urethritis; HIV; antibiotic resistance; ciprofloxacin; quinolones; men having sex with men.**

(Accepted May 18, 2009.)

Acta Derm Venereol 2009; 89: 484–487.

David Farhi, Hôpital Cochin, Department of Dermatology and Venereology, 27, rue du faubourg Saint Jacques, FR-75014 Paris, France. E-mail: david.farhi@cch.aphp.fr

Neisseria gonorrhoeae (NG) is responsible for an acute sexually transmitted infection (STI) that may involve urethral, cervical, anorectal and pharyngeal sites. Complications include epididymo-orchitis, pelvic inflammatory disease (endometritis, salpingitis), keratoconjunctivitis, tenosynovitis, septic arthritis and sepsis. Untreated infection can lead to infertility, ectopic pregnancy and chronic pelvic pain.

Moreover, NG infection increases the risk of HIV transmission. In the USA, NG infection is the second most commonly reported notifiable disease, and its prevalence among persons aged 14–39 years is approx-

imately 0.25% (1). The incidence of NG urethritis in France remains between 61 and 105 cases per 100,000 population (2).

Several molecular mechanisms may lead to antimicrobial resistance of NG. Penicillinase-producing NG strains were first reported in the USA in 1976, and penicillin is no longer recommended for the treatment of NG infection since 1986. Quinolone-resistant NG (QRNG) were first reported in 1992 in Australia (3), in 1994 in the UK (4) and in 1995 in the USA (5). A recent review showed that, by 2004, QRNG rates $\geq 15\%$ were reported in the USA, and in Western Europe, Africa, Oceania and Asia (1). Consistent with the World Health Organization (WHO) recommendation that an antimicrobial associated with a resistance of $\geq 5\%$ of strains should be abandoned, fluoroquinolones are no longer recommended for the treatment of NG in the general population in several countries, including France, since 2005 (6) and the USA since 2007 (7).

In a previous report, we showed that the rate of QRNG reached a peak of 30% in Paris in 2004, with higher rates among men having sex with men (MSM), HIV-positive patients and patients with more than 5 partners during the preceding year (8). Following the French guidelines of 2005 (6) and the theoretical subsequent fall in the use of fluoroquinolones for the treatment of NG infections, one could speculate that the decreased pressure for selection should be associated with a parallel decrease in QRNG rates. However, recent studies conducted in regions where exposure to quinolones since the turn of the millennium has been negligible, such as China (9) and Australia (10) showed persistent increases in QRNG rates.

We performed a prospective study to assess the QRNG rate in Paris over the period 2005 to 2007. In addition, we aimed to identify peculiar groups of patients associated with higher rates of QRNG. Finally, we also report here our survey of the susceptibility of NG strains to four other antibiotics (ceftriaxone, spectinomycin, penicillin G and tetracycline).

PATIENTS AND METHODS

Patients and setting

From 1 January 2005 through 31 December 2007, 115 isolates were recovered from 110 consecutive patients diagnosed with go-

gonorrhoea, in a public venereal clinic. Our study sample represents 18.5% of the 620 NG infections diagnosed in the nine existing Parisian venereology clinics during the period 2005 to 2007.

Patients came mainly from Paris (60%) or its suburbs (40%). They usually referred directly, either for high-risk sexual behaviour or for genital symptoms. These referral criteria were constant throughout the study period. Demographic and clinical data (age, gender, group of sexual transmission, number of partners in the preceding year, site of infection, and previous history of STI) were prospectively collected using standardized medical forms. Over the study period, first-line treatment of gonorrhoea relied on a single intramuscular injection of ceftriaxone (250 mg), according to the French guidelines of 2005 (6).

Case definition

A gonococcal infection was defined by the demonstration of the presence of NG in a swabbing sample, by classical culture. Patients were screened for gonorrhoea if they had genital, rectal and/or pharyngeal discharge and/or pain, or any context of a suspicion of recent STI. Samples were collected from urethral discharge, vaginal discharge, pharyngeal and rectal swabbing. Thus, a patient may present simultaneously with more than one documented infected anatomical site.

The indications and method of swabbing were constant over the period 2000 to 2007, as well as methods for isolation, culture and bacterial identification of NG, which were described previously (11). Hence, the results of the present study can be compared with those of our previous report from 2000 to 2004 (8).

Antibiotic susceptibility assessments

Ciprofloxacin, ceftriaxone, spectinomycin, and tetracycline NG susceptibilities were tested by the agar plate diffusion method using PolyViteX agar medium. The β -lactamase production was detected using the nitrocephin test (Cefinase[®], BD BBL, Sparks, MD, USA). The minimum inhibitory concentration (MIC) for penicillin G was measured by the E-test[®] method. The MIC for ciprofloxacin was measured using the E-test method, in addition to the agar diffusion method. Antibiotic susceptibility results were confirmed by the national reference centre for gonococcus (Centre National de Référence des Gonocoques).

The MIC breakpoints ($S \leq R >$, mg/l) used for assessing antibiotic susceptibilities were identical for the EUCAST (European Committee on Antimicrobial Susceptibility Testing) (12) and the CASFM (Comité de l'Antibiogramme de la Société Française de Microbiologie) 2008 recommendations, for the following antibiotics (13): ciprofloxacin (0.03/0.06), penicillin G (0.06/1.0), ceftriaxone (0.12/0.12) and spectinomycin (64/64). For tetracycline, we used CASFM breakpoints (1.0/4.0), which

Table I. Demographic and epidemiological features of 115 consecutive cases of *Neisseria gonorrhoeae* infection

Features	
Total number of cases, <i>n</i> (%)	115 (100)
Median age (interquartile range), years, mean (SD)	30 (25–37)
Cases occurring in men, <i>n</i> (%)	110 (95.6)
Cases occurring in MSM, <i>n</i> (%)	84 (73.0)
Partners during the preceding 12 months, <i>n</i> (%)	
≤ 4	48 (41.7)
5–10	23 (20.0)
≥ 11	44 (38.3)
Condom never used, <i>n</i> (%)	19 (18.1) ¹
Positive HIV serology, <i>n</i> (%)	21 (18.4) ²

¹of 105 men; ²of 114 men

MSM: men having sex with men

are different from those of EUCAST (0.5/1.0). The antibiotic susceptibility assessments and MIC breakpoint were unchanged since that of our previous report from 2000 to 2004 (8).

Statistical analyses

The main outcome was the rate of QRNG among the cohort of patients with NG infection who referred to our venereal clinic during the study period. The association of antimicrobial resistance with demographic or clinical factors was analysed with R software 2.2.1 (R Development Core Team, Austria, 2005). Qualitative data were analysed using the Fischer exact test. Quantitative data were using the Kruskal-Wallis one-way analysis. The significance threshold was settled at the two-sided $p < 0.05$.

RESULTS

Patients

Over the period 2005 to 2007, a total of 115 NG infections were diagnosed in 110 patients, among a total of 29,594 referrals in our venereal clinic (0.39%). Five of the 110 patients (4.5%) had more than one infection during the study period.

The demographic and epidemiological features of all consecutive cases of NG infections are summarized in Table I. Of 115 cases of NG infections, 110 were diagnosed in men (95.6%) and 5 in women (4.4%). The median age was 30.0 years (range 17–67 years). Almost 20% of the patients were HIV-positive.

Sites of *Neisseria gonorrhoeae* isolation

NG infection was microbiologically documented in all cases. The site of NG isolation was the urethra in 86 cases (74.8%), the anorectal area in 22 cases (19.1%), the pharynx and the anorectal area in 9 cases (7.8%), and the anorectal, urethral and pharyngeal areas in 2 cases (1.7%).

Rates of antibiotic resistant *Neisseria gonorrhoeae*

Over the period 2005 to 2007, the rate of QRNG was 37.4% (43/115), and the rate of intermediate ciprofloxacin susceptibility was 2.6% (3/115). Compared with our report from 2000 to 2004, the rate of QRNG increased markedly, both overall and according to sexual orientation and the HIV status (Table II).

None of the strains was resistant to ceftriaxone or spectinomycin. The rate of resistance to tetracycline was 17.4% (20/115). The rates of resistance and intermediate susceptibility to penicillin G were 11.3% (13/115) and 60.0% (69/115), respectively. Of the 13 penicillin G resistant strains, 11 produced β -lactamase (9.6% of the 115 cases of NG infections).

Factors associated with Quinolone-resistant *Neisseria gonorrhoeae*

None of the studied factors was significantly related to the QRNG rate.

Table II. Rate of quinolone-resistant *Neisseria gonorrhoeae* (QRNG) during 2000 to 2004 and 2005 to 2007 (figures from ref. 8), overall and according to sexual orientation and HIV-serology

	Number of QRNG (%)	
	2000–2004 (8)	2005 to 2007
Overall, n (%)	22/153 (14.4)	43/115 (37.4)
Sexual orientation, n (%)		
MSM	20/120 (16.7)	34/84 (40.5)
Heterosexual men	2/28 (7.1)	9/31 (29.0)
HIV serology, n (%)		
Positive	8/39 (20.5)	8/24 (33.3)
Negative	13/109 (11.9)	35/91 (38.5)

MSM: men having sex with men

None of the 5 cases occurring in female patients vs. 43 of the 110 cases occurring in male patients (39.1%) were QRNG infection ($p=0.16$). The QRNG Rate was not significantly different between heterosexual and MSM (9/31, 29.0% vs. 34/84, 40.5%; $p=0.27$), and between HIV-negative and HIV-positive patients (35/91, 38.5% vs. 8/24, 33.3%; $p=0.88$).

The rate of QRNG was not significantly associated with the gender, the number of sexual partners during the preceding year or the presence of previous STI (hepatitis B, syphilis, genital herpes and *Chlamydia trachomatis* infection). Similarly, the rate of QRNG was not significantly related to the susceptibility to penicillin G or tetracycline.

DISCUSSION

As shown in Table II, the rate of QRNG in Paris increased from 14% to 37% between the periods 2000 to 2004 and 2005 to 2008, despite a theoretical fall in the use of ciprofloxacin for treating gonorrhoeae. Even more dramatic increases in QRNG rates have been reported worldwide, despite regional recommendations precluding the use of fluoroquinolones for the first-line treatment of gonorrhoeae. Su et al (9) studied the antibiotic susceptibility of NG strains in Nanjing (China) between 1999 and 2006. In Nanjing, a surveillance programme of NG susceptibility to fluoroquinolones was launched in 1994, when the QRNG rate was 2.9%. Yet, Su et al. observed a dramatic rise of QRNG rates from 17.5% in 1995 to 83.9% in 1999 and 99.0% in 2006. Moreover, in 2006, most resistance were at a high level ($MIC_{90} \geq 8$ mg/l). Interestingly, in 2004 to 2006, Tapsall et al. (10) reported rapidly increasing NG resistance to penicillin and fluoroquinolones in areas of Australia where the use of these agents had been discontinued for gonorrhoeae treatment.

Several hypotheses can be raised to explain this continuous and sheer rise in QRNG rates in developed countries in general and, peculiarly, in France: (i) the inadequate persisting use of fluoroquinolones for the treatment of NG infections; (ii) the spread of QRNG

strains from distant reservoirs, such as South-East Asia, where overuse and misuse of antibiotics are widespread; (iii) the permanent selective pressure on patients with undiagnosed carriage of NG strains by a pervasive use of fluoroquinolones prescribed for other infectious diseases. Obviously, studies are needed to appraise physicians' adherence to national guidelines and the actual use of antibiotics for NG infections. To our knowledge, such survey has not been performed in France over the past decade.

We found that the rate of QRNG is not significantly related to sexual orientation, HIV-status, number of sexual partners during the preceding years and past history of STI. However, it is of note that the QRNG rate was higher among MSM (40.5%) than among heterosexual men (29.0%), and that the absence of significant difference between these groups could be due to the small sample size.

Interestingly, the rise of QRNG has been proportionally greater (when considering the ratio *increase/initial QRNG rate*) for groups that were previously considered at lower risk of QRNG, namely heterosexual men and HIV-negative men (8). Besides, we also confirm that NG strains remains constantly susceptible to ceftriaxone and spectinomycin. Overall, these results corroborate that the French guidelines of 2005 for the management of NG infections are still relevant in 2008 (6).

Over the past decade, the increase in QRNG rates in France has been dramatic. For instance, these rates were 0.70% in 1998, 3.3% in 2000, 12.8% in 2003 and 31.6% in 2005 (14). The characteristics of our study population are comparable with those of a 2004 to 2006 national survey of NG infections, which reported that 96% of the cases occurred in men, 69% occurred in MSM and 16% occurred in HIV-positive patients (15). These findings suggest that our antibiotic susceptibility data may reflect national trends.

Recent national surveys in the rest of Europe showed similar trends. For instance, in England and Wales, in 2006, 26.5% and 1.7% of NG strains were respectively resistant and intermediately resistant to ciprofloxacin (16). As in our study, the recently observed increase in the QRNG rate was proportionally greater among heterosexual men (16). Other recently reported QRNG rates include 48% in Southern Germany (17) and 59% in Austria (18).

To our knowledge, only one case of spectinomycin resistant and no cases of ceftriaxone resistant NG strains have been reported in France (8, 15). Accordingly, in recent Western surveys, NG strains remain almost constantly susceptible to ceftriaxone and spectinomycin. Through 2006, in England and Wales, no NG strains demonstrated resistance to ceftriaxone and spectinomycin (16). Similarly, a report of 65 NG strains in Southern Germany between July 2004 and June 2005 demonstrated no resistance to ceftriaxone or spectino-

mycin (17). In a report of NG antibiotic susceptibility in Vienna (Austria) in 1999 to 2002, only one of 104 isolates demonstrated resistance to ceftriaxone (18). During the 1986 to 2005 period, only 4 ceftriaxone-resistant NG strains – all of them between 1987 and 1997 (19) – and 5 spectinomycin-resistant NG strains – all of them between 1988 and 1994 (19) – were isolated in the USA through the Gonococcal Isolate Surveillance Project network. However, spectinomycin is scarcely used for NG infections in Western countries, and, since high-level resistance to spectinomycin can result from a single-step mutation, the actual susceptibility of NG strains to spectinomycin should be interpreted with caution (1).

Finally, we showed that only a minority of NG strains with a decreased susceptibility to penicillin produce a β -lactamase (11/82, 13.4%), and thus it can be inferred that the majority of decreased NG susceptibilities to penicillin result from a modification of the penicillin-binding proteins (20).

In summary, our study confirms the relevance of the 2005 French guidelines for the treatment of NG infections (6). The rate of QRNG is still increasing in Paris, and this rise is peculiarly obvious among heterosexual and HIV-negative patients. Practically, an intramuscular single-dose of ceftriaxone remains the gold standard treatment for non-complicated NG infection at any anatomical sites. In patients intolerant to ceftriaxone, spectinomycin is good alternative in non-pharyngeal NG infections. For pharyngeal NG infections in patients intolerant to ceftriaxone, ciprofloxacin may be considered only if susceptibility to this compound is documented.

ACKNOWLEDGEMENTS

We are indebted to Drs Dany Bakhos, Philippe Dhotte, Salim Hilab, Randa Jdid and Christina Pantoja, for their contribution to the clinical management of the patients included in this study. We are also grateful to Chantal Constantin, Soline Dautheville, Nicole Savaglio and Annunziata Urbano, for their assistance in the data collection.

The authors declare no conflict of interest.

REFERENCES

- Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhoea in adults in the United States. *Clin Infect Dis* 2007; 44 Suppl 3:S84–S101.
- Farhi D, Aynaud O, Dupin N. Ecoulement urétral chez l'homme. *Pelv Perineol* 2008; 3: 1–7.
- Tapsall JW, Shultz TR, Lovett R, Munro R. Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. *Med J Aust* 1992; 156: 143.
- Birley H, McDonald P, Carey P, Fletcher J. High level ciprofloxacin resistance in *Neisseria gonorrhoeae*. *Genitourin Med* 1994; 70: 292–293.
- Fluoroquinolone resistance in *Neisseria gonorrhoeae* – Colorado and Washington, 1995. *MMWR Morb Mortal Wkly Rep* 1995; 44: 761–764.
- Afssaps. Mise au point. Le traitement antibiotique probabiliste des urétrites et cervicites non compliquées. [cited 2008 Jun 21]. Available from: URL: <http://www.afssaps.sante.gouv.fr/pdf/10/mp140905.pdf>
- Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. *MMWR Morb Mortal Wkly Rep* 2007; 56: 332–336.
- Farhi D, Gerhardt P, Falissard B, Poupet H, Poyart C, Dupin N. Increasing rates of quinolone-resistant *Neisseria gonorrhoeae* in Paris, France. *J Eur Acad Dermatol Venereol* 2007; 21: 818–821.
- Su X, Jiang F, Qimuge, Dai X, Sun H, Ye S. Surveillance of antimicrobial susceptibilities in *Neisseria gonorrhoeae* in Nanjing, China, 1999–2006. *Sex Transm Dis* 2007; 34: 995–999.
- Tapsall JW, Limnios EA, Murphy D. Analysis of trends in antimicrobial resistance in *Neisseria gonorrhoeae* isolated in Australia, 1997–2006. *J Antimicrob Chemother* 2008; 61: 150–155.
- Ison CA, Woodford PJ, Madders H, Claydon E. Drift in susceptibility of *Neisseria gonorrhoeae* to ciprofloxacin and emergence of therapeutic failure. *Antimicrob Agents Chemother* 1998; 42: 2919–2922.
- EUCAST, inventor Clinical breakpoints. [cited 2008 Jun 25]. Available from: URL: <http://www.srga.org/eucastwt/MICTAB/index.html>. 2008
- Soussy CJ. Communiqué 2008 du Comité de l'Antibiogramme de la Société Française de Microbiologie (CASFM). *Online Pub Jan* 2008. [cited 2008 June 25]. Available from: URL: <http://www.sfm.asso.fr/publi/general.php?pa=1>. 2008
- INVS. Réseau RENAGO. [Epidemiology of sexually transmitted infections in France]. [cited 2008 April 19]. Available from: URL: http://www.invs.sante.fr/publications/2007/actualites_vih_sida_ist_2007/2-IST%20nov%202007.pdf. 2007
- INVS. Réseau RENAGO. [Characteristics of *Neisseria gonorrhoeae* resistance to antibiotics]. [cited 2008 April 19]. Available from: URL: http://www.invs.sante.fr/surveillance/resistance/fiche_neisseria_gonorrhoeae.htm. 2007
- GRASP. The Gonococcal Resistance to Antimicrobials Surveillance Programme. Annual Report 2006. [cited 2008 April 19]. Available from: URL: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947393147
- Enders M, Turnwald-Maschler A, Regnath T. Antimicrobial resistance of *Neisseria gonorrhoeae* isolates from the Stuttgart and Heidelberg areas of southern Germany. *Eur J Clin Microbiol Infect Dis* 2006; 25: 318–322.
- Uthman A, Heller-Vitouch C, Sary A, Bilina A, Kuchinka-Koch A, Soltz-Szots J, et al. High-frequency of quinolone-resistant *Neisseria gonorrhoeae* in Austria with a common pattern of triple mutations in GyrA and ParC genes. *Sex Transm Dis* 2004; 31: 616–618.
- Gonococcal Isolate Surveillance Project (GISP). Annual Report 2005. [cited 2008 April 19]. Available from: URL: http://www.cdc.gov/std/Gisp2005/GISP_Surv_Supp2005_s-hort.pdf. 2007
- Rice RJ, Knapp JS. Antimicrobial susceptibilities of *Neisseria gonorrhoeae* strains representing five distinct resistance phenotypes. *Antimicrob Agents Chemother* 1994; 38: 155–158.